嵌合抗原受体T细胞治疗多发性骨髓瘤新进展  

New progress of chimeric antigen receptor T cells in the treatment of multiple myeloma

作　　者：陈瑜[1] 尤良顺[1] 孟海涛[1] 杨敏[1] Chen Yu;You Liangshun;Meng Haitao;Yang Min(Department of Hematology,the First Affiliated Hospital Zhejiang University School of Medicine,Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院血液科、浙江省血液肿瘤(诊治)重点实验室,杭州310003

出　　处：《中华移植杂志（电子版）》2023年第5期313-320,共8页Chinese Journal of Transplantation(Electronic Edition)

基　　金：浙江省公益重点项目(LZ23H080002)。

摘　　要：多发性骨髓瘤(MM)是恶性浆细胞病,是第二大常见的血液系统恶性肿瘤,目前尚缺乏治愈的手段。尽管新的药物不断涌现,但是MM的耐药和复发仍是目前研究的重点,迫切需要更好的疗法。嵌合抗原受体T细胞(CAR-T)疗法是近几年新兴的治疗方式,在MM治疗中表现出了较好的治疗前景,为治愈MM带来希望。本文从CAR-T疗法临床疗效、治疗安全性和可及性等方面阐述其在MM治疗中的新进展,以期进一步优化治疗策略。Multiple myeloma(MM)is a kind of malignant tumor of plasma cells,ranking as the second most common hematological malignancy,and has no cure.Despite the introduction of new drugs,the challenge of drug resistance and disease relapse in MM remains a primary focus of research,highlighting the urgent need for improved treatment options.Chimeric antigen receptor T cells(CAR-T)therapy is a new promising approach in recent years,which brings hope for curing of MM.This paper summarizes the advancements of CAR-T therapy in the treatment of MM,covering the aspects of clinical efficacy,safety and accessibility,with the aim of optimizing the treatment strategy.

关 键 词：多发性骨髓瘤 嵌合抗原受体T细胞 靶点选择 不良反应 

分 类 号：R733.3[医药卫生—肿瘤]